B-Cell Combination Therapy for IgM and Drug Resistance Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hyperproliferative disorders, particularly B-cell disorders such as non-Hodgkin's lymphomas and chronic lymphocytic leukemia, are difficult to treat effectively, with low survival rates and challenges in managing serum IgM levels and bone marrow involvement, necessitating new therapeutic approaches.
Innovation Solution
Combination therapies involving targeted B-cell therapies like BTK inhibitors, BCL-2 inhibitors, proteasome inhibitors, and IL-6 modulators, optionally with CXCR4 inhibitors, to target and modulate key signaling pathways and reduce IgM secretion and bone marrow adhesion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent targeted B-cell therapy is used, then treatment simplicity is maintained, but treatment efficacy and survival rates are insufficient
Solution Approach 1:
The patent combines multiple targeted B-cell therapies (BTK inhibitors, BCL-2 inhibitors, proteasome inhibitors) with IL-6 modulators and CXCR4 inhibitors into combination therapy regimens. This merging of multiple mechanisms of action addresses the limitation of single-agent therapy by attacking the malignancy through multiple simultaneous pathways, thereby improving treatment efficacy and survival rates while managing the complexity through structured combination protocols
2Reliability
If conventional therapy is used, then treatment approach is simple, but serum IgM levels and bone marrow involvement are not effectively controlled
Solution Approach 1:
The patent segments the therapy into distinct functional components: BTK inhibitors for signal transduction blockade, BCL-2 inhibitors for apoptosis promotion, proteasome inhibitors for protein degradation, IL-6 modulators for cytokine suppression, and CXCR4 inhibitors for chemokine receptor blockade. This segmentation allows each component to target specific pathways responsible for IgM production and bone marrow involvement, achieving comprehensive control through divided functional actions
3Reliability
If standard therapy regimens are used, then treatment protocol is straightforward, but drug resistance develops and survival rates remain low
Solution Approach 1:
The patent employs composite therapy regimens that integrate multiple drugs with different mechanisms of action into unified treatment protocols. This composite approach creates synergistic effects where the combination of BTK inhibitors, BCL-2 inhibitors, proteasome inhibitors, IL-6 modulators, and CXCR4 inhibitors produces greater overall efficacy than individual agents, thereby improving survival rates by creating therapeutic compositions that resist the development of resistance through multiple simultaneous targeting mechanisms
Data Source
AI summary
The present invention provides methods of treating B-cell disorders with combination therapies comprising the use of (i) a targeted B-cell therapy; (ii) an IL-6 modulator, and (iii) a CXCR4 inhibitor; or (i) a targeted B-cell therapy and (II) an IL-6 modulator. In one aspect, the present invention provides a method of treating a hyperproliferative disorder in a patient in need thereof, comprising administering to the patient an effective amount of a targeted B-cell therapy in combination with an effective amount of an IL-6 modulator, and optionally in combination with an effective amount of a CXCR4 inhibitor.